Neurotech Provides Update on BLA for NT-501 as a ...
Neurotech Pharmaceuticals announced an FDA extension of the PDUFA goal date for NT-501's BLA to March 18, 2025, to review additional data. NT-501, using the ECT platform, aims to treat MacTel, a rare neurodegenerative disease affecting central vision, by delivering CNTF for chronic retinal diseases.
Reference News
Neurotech Provides Update on BLA for NT-501 as a ...
Neurotech Pharmaceuticals announced an FDA extension of the PDUFA goal date for NT-501's BLA to March 18, 2025, to review additional data. NT-501, using the ECT platform, aims to treat MacTel, a rare neurodegenerative disease affecting central vision, by delivering CNTF for chronic retinal diseases.